References
- Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A Global Overview and Recent Trends. Eur Urol 2017; 71: 96-108. doi: 10.1016/j.eururo.2016.06.010
- Mariappan P, Fineron P, O’Donnell M, Gailer RM, Watson DJ, Smith G, et al. Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. World J Urol 2020; [Ahead of print]. doi: 10.1007/s00345-020-03180-5
- Babjuk M, Burger M, Compérat E, Gontero P, Mostafid AH, Palou J, et al. EAU Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2020. European Association of Urology Guidelines 2020 Edition. Presented at the EAU Annual Congress Amsterdam 2020. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020.
- Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015; 33: 66.e25-31. doi: 10.1016/j. urolonc.2014.06.008
- Trinh TW, Glazer DI, Sadow CA, Sahni VA, Geller NL, Silverman SG. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. Abdom Radiol 2018; 43: 663-71. doi: 10.1007/s00261-017-1249-6
- Kim J, Kim WT, Kim WJ. Advances in urinary biomarker discovery in urological research. Investig Clin Urol 2020; 61: S8-22. doi: 10.4111/icu.2020.61. S1.S8.
- Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int 2018; 121: 29-37. doi: 10.1111/bju.14019
- Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017; 71: 447-61. doi: 10.1016/j.eururo.2016.05.041
- Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurtycz DF, et al. The Paris System for reporting urinary cytology: the quest to develop a standardized terminology. Adv Anat Pathol 2016; 23: 193-201. doi: 10.1097/PAP.0000000000000118
- Wallace E, Higuchi R, Satya M, McCann L, Sin MLY, Bridge JA, et al. Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection. J Urol 2018; 199: 655-62. doi: 10.1016/j.juro.2017.09.141
- Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Eighth edition. Chichester, West Sussex, UK; Hoboken, NY: John Wiley & Sons, Inc.; 2017.
- Moch H, Reuter VE, Humphrey PA, Ulbright TM. WHO classification of tumours of the urinary system and male genital organs. International Agency for Research on Cancer; 2016.
- Hentschel AE, van Rhijn BWG, Brundl J, Comperat EM, Plass K, Rodriguez O, et al. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Urol Oncol 2020; 38: 440-8. doi: 10.1016/j.urolonc.2019.10.002
- The Paris System for reporting urinary cytology. Rosenthal DL, Wojcik EM, Kurtycz DFI, editors. New York, NY: Springer Science and Business Media; 2015.
- Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002; 41: 284-9. doi: 10.1016/s0302-2838(02)00006-4
- Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-25. doi: 10.1016/j.eururo.2009.01.002
- Hurle R, Casale P, Saita A, Colombo P, Elefante GM, Lughezzani G, et al. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. World J Urol 2020; 38: 2215-20. doi: 10.1007/s00345-019-03002-3
- Valenberg F, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol 2019; 75: 853-60. doi: 10.1016/j. eururo.2018.11.055
- Elia DC, Pycha A, Folchini DM, Mian C, Hanspeter E, Schwienbacher C, et al. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. J Clin Pathol 2019; 72: 140-4. doi: 10.1136/jclinpath-2018-205393
- Soria F, Droller MJ, Lotan Y, Gontero P, D’Andrea D, Gust KM, et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol 2018; 36: 1981-95. doi: 10.1007/s00345-018-2380-x
- Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001; 165: 1124-8. PMID: 11257652
- Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006; 49: 303-6. doi: 10.1016/j.eururo.2005.12.029